Highlights Femasys Inc.

Equities

FEMY

US31447E1055

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
1.28 ^USD	+1.59%		-7.25%	+31.28%

May. 09	Femasys Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	Earnings Flash (FEMY) FEMASYS Reports Q1 Revenue $271,140	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Femasys Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Earnings Flash (FEMY) FEMASYS Reports Q1 Revenue $271,140	May. 09	MT
Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Femasys Inc. Announces Positive Topline Data from Pivotal Trial for Its Fda-Cleared Femaseed®? for the Treatment of Infertility	Mar. 20	CI
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution	Mar. 06	CI
Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At UC Davis Medical Center, A Hub for Innovation and Groundbreaking Research in Health Care for Women	Jan. 26	CI
Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At University of Utah	Jan. 23	CI
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine	Dec. 15	CI
Femasys Inc. Completes Enrollment of Femaseed Pivotal Trial in Support of Commercial Launch	Nov. 29	CI
Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (FEMY) FEMASYS Reports Q3 Revenue $86,186	Nov. 14	MT
Femasys Inc. Successfully Completes the Stage 2 European Union (EU) Medical Device Regulation	23-10-26	CI
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate	23-09-27	CI
Femasys Gets US FDA Approval to Market Infertility Treatment Procedure FemaSeed; Shares Rise After Hours	23-09-25	MT
Femasys Gets License to Sell Products Directly in Canada	23-08-31	MT
Femasys Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (FEMY) FEMASYS Reports Q2 Revenue $320,514	23-08-10	MT
Femasys Inc. Initiates Enrollment in Pivotal Trial of Its Permanent Birth Control Candidate FemBloc	23-08-03	CI
Femasys Gets Notice of Allowance for Female Permanent Birth Control Product Candidate; Stock Surges	23-07-27	MT
Femasys Inc. Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, A Non-Surgical Alternative for Women	23-06-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Femasys Inc.

Equities

FEMY

US31447E1055

Highlights

Filters